In summary, the reduced levels of cell-associated AXL receptor in patients’ DCs and higher serum concentrations of GAS6 decoy receptor (sAXL) may prevent engagement of GAS6-AXL inhibitory pathway in RA DCs, particularly in naive-to-treatment early RA. This evidence concerns the gene GAS6 and rheumatoid arthritis.